AKAjmal Khan

Ajmal Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajmal Khan has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Alok Nath

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow

    9 shared publications
  • Zia Hashim

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    7 shared publications
  • Alok Nath

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    6 shared publications
  • Mansi Gupta

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    6 shared publications
  • Zia Hashim

    Department of Pulmonary Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    6 shared publications
  • Mansi Gupta

    Department of Pulmonary Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    4 shared publications

Latest Publications

  • Open Access

    Role of bronchoscopic intervention in endobronchial mesenchymal tumours – A retrospective study and systematic review of literature

    by Yash Jagdhari, Gundmi Sumanth, Pallavi Prasad, Nandita Chaudhary, Areekkara Poduvattil Prasanth, Zia Hashim, Mansi Gupta, Alok Nath, Zafar Neyaz, Ajmal Khan

    Background: Primary pulmonary mesenchymal tumours (PMTs) are rare, and their management strategies are heterogeneous due to the lack of standardised treatment protocols. Given the morbidity associated with surgical resection, less invasive therapeutic options are warranted. Therefore, we aimed to assess the role of bronchoscopic interventions in endobronchial PMTs. Methods: We retrospectively reviewed the records (January 2018 to June 2025) of patients who underwent bronchoscopic intervention for endobronchial PMT. We evaluated the clinical characteristics, feasibility, complication rates and follow-up outcomes of bronchoscopic interventions. A systematic review of the literature was performed to identify all reported adult patients who underwent bronchoscopic intervention, enabling comparison with our case series. Results: Eighteen patients (12 males) with a mean age of 40.0 ± 15.2 years (range, 18–67) underwent bronchoscopic interventions. Dyspnoea (83.4%), cough (72.2%) and chest pain (44.5%) were the most common presenting symptoms, while stridor was present in 10 (55.6%) patients. Despite central airway obstruction, the mean duration of symptoms prior to diagnosis was 7.6 ± 8.6 months (range 2–34). Bronchoscopic interventions successfully achieved >90% luminal patency after lesion removal in most patients. These results are consistent with our accompanying systematic review of 152 reports, which synthesised a comparative literature cohort of 204 patients across four primary mesenchymal tumour subtypes. Conclusion: Bronchoscopic interventions represent a feasible, effective and low-risk approach for immediate and lasting relief of airway obstruction in PMTs. They can be considered in selected patients, potentially obviating the need for a conventional surgical approach.

  • Endobronchial Ultrasound-Guided Fine Needle Biopsy in the Diagnosis of Mediastinal Lymphadenopathy

    by Ajmal Khan, Atul Tiwari, Mansi Gupta, Zia Hashim, Alok Nath, Vinita Agrawal, Ojas Gupta, Anup Kumar

    Background: The comparative sampling efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) needles in mediastinal lymphadenopathy remains unclear. Would the fine needle biopsy (FNB), with its Franseen design, provide better results than the fine needle aspiration (FNA) during EBUS-TBNA? Methods: We performed a single-center, investigator-initiated, single-blinded, randomized, parallel-group, superiority trial between August 2022 and July 2023. Consecutive patients were randomly assigned (1:1) to undergo EBUS-TBNA with either 19-gauge (G) FNA or 22-G FNB. The primary endpoint was the diagnostic yield, while the secondary endpoints were specimen adequacy and complication rates. Results: The study included 150 patients with a mean age of 44.5±15.1 years (50.7% female patients). The diagnostic yield of FNB was not significantly different from FNA (94.7% vs. 89.3%; difference, 5.4%; 95% CI: −4.0% to 15.0%; P =0.23). Despite this, FNB had a higher rate of adequate tissue (98.6% vs. 86.7%; difference, 11.9%; 95% CI: 4.0%-22.0%; P P P =0.016) in post hoc analysis; however, this should be considered a hypothesis-generating finding. All procedures were well tolerated except for minor bleeding. Conclusion: Despite similar diagnostic yields, FNB was more effective than FNA in providing larger, adequate core tissue samples. This improvement in specimen quality may suggest a potential clinical benefit for comprehensive diagnosis and advanced pathologic work-up.

  • Open Access

    Prevalence of Relapse in Pulmonary Sarcoidosis: A Systematic Review

    by Zia Hashim, Robert Baughman, Ritesh Agarwal, Naresh Kumar Tripathy, Mansi Gupta, Ajmal Khan, Ajit Kumar Jha, Anup Kumar, Alok Nath

    Background and objectiveRelapse after treatment discontinuation or reduction frequently occurs in pulmonary sarcoidosis (PS), but reported rates vary widely. We conducted a systematic review and meta-analysis to estimate relapse prevalence and evaluate risk factors.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar from inception through January 2026 for studies reporting relapse prevalence in PS. Two reviewers independently extracted data on relapse prevalence, timing, definitions, and predictors, and assessed study quality using the Hoy et al. tool. We calculated pooled prevalence using random effects models, assessed heterogeneity using I2, and performed subgroup analyses and meta-regression.ResultsWe included 51 studies comprising 6076 patients; 3682 were followed up, and 1442 relapsed. Pooled relapse prevalence was 0.39 (95% CI, 0.33-0.45) with substantial heterogeneity (I2=94%). Relapse prevalence was lower in prospective (0.31, 95% CI: 0.25-0.37) than retrospective (0.45, 95% CI: 0.36-0.54) studies. Only 23 (45%) studies provided explicit relapse definitions, which varied across clinical, radiological, functional, and biomarker criteria. Advanced radiographic stage was associated with higher relapse odds than stage I (log OR 0.55-1.04, p<0.05), and Black race with higher odds than White race (log OR 0.91, p<0.01). Relapse prevalence did not differ between clinical-only versus composite definitions.ConclusionsApproximately two-fifths of PS patients relapse after treatment reduction or discontinuation. Marked heterogeneity in relapse definitions and observational study designs underscores the need for standardized criteria. Clinical assessment appears comparable to complex definitions for assessing relapse.

  • Open Access

    Serum metabolic disparity between patients with lymph node tuberculosis and patients with sarcoidosis: towards differential diagnosis

    by Alok Nath, Sachin Yadav, Kritika Singh, Vikas Agarwal, Ajmal Khan, Zia Hashim, Mansi Gupta, Dinesh Kumar

    Sarcoidosis (SAR) and lymph-node tuberculosis (LNTB) are granulomatous diseases that present diagnostic challenges, especially in TB-endemic regions. We hypothesized that serum-metabolic profiles would help in differentiating SARs from LNTBs. This study aimed to identify serum metabolic biomarkers to distinguish SAR from LNTB using NMR-based metabolomics analysis. Serum samples were collected from 26 SAR and 22 LNTB patients. The serum metabolic profiles were measured using 800 MHz NMR spectroscopy and quantified using the commercial software CHENOMX. The serum metabolic profiles were compared using multivariate partial least squares discriminant analysis (PLS-DA), and potential discriminatory metabolites were identified using variable importance in projection (VIP) scores and subsequently evaluated for statistical significance using a volcano plot. The diagnostic potential of the discriminatory metabolites was evaluated using receiver operating characteristic (ROC) curve analysis. PLS-DA demonstrated significant metabolic disparity between the SAR and LNTB groups. The key metabolic features identified included elevated levels of glutamate, pyroglutamate, acetate, and leucine and a decreased glutamate-to-glutamine ratio (EQR) and decreased levels of glutamine, pyruvate, and myo-inositol in TB patients. These metabolic changes suggest that TB-infection involves activated glutaminolysis and elevated host lipid metabolism. ROC curve analysis revealed several metabolites with high diagnostic potential (AUC > 0.8), including glutamate, pyroglutamate, and glutamine (AUC > 0.98). In conclusion, this study underscores the potential of serum metabolic profiling as a noninvasive tool for distinguishing SARs from LNTBs. However, further studies are imperative to validate these findings on independent patient cohorts and to facilitate their integration into routine clinical practice.


  • Open Access

    Relationship of fractional exhaled nitric oxide with blood eosinophilia in characterizing type-2 airway inflammation in treatment-naïve patients with chronic obstructive pulmonary disease

    by Riksoam Chatterjee, Mansi Gupta, Zia Hashim, Ajmal Khan, Alok Nath, Vikas Aggarwal

    Fractional exhaled nitric oxide (FeNO), a sensitive and reproducible, non-invasive biomarker for type-2 (T2) inflammation in asthma, remains underutilized in chronic obstructive pulmonary disease (COPD). We investigated the potential role of FeNO and its relationship with blood eosinophilia in characterizing T2 airway inflammation in COPD. A single-center prospective observational study was conducted in 75 treatment-naïve adult patients with stable COPD and 75 age-sex-matched controls. The Global Initiative for Chronic Obstructive Lung Disease criteria were used for the diagnosis of COPD. FeNO levels were compared with clinico-radiological features, pulmonary functions, and other markers of T2 inflammation in COPD. Participants in the COPD subgroup had a median age of 62 (55.0, 69.0) years with a male predominance (77.3%). The median FeNO value was 27.0 ppb (19.0, 39.0) in COPD and 14.0 ppb (10.0, 20.0) in controls (p<0.001). FeNO values were categorized as low (≤25 ppb), intermediate (25-50 ppb), and high (≥50 ppb), with 57.3% of COPD patients having intermediate to high FeNO. In contrast, 46.7% of these patients had an absolute eosinophil count (AEC) ≥300/mm³. Higher values of FeNO in COPD were associated with the history of atopy (p<0.001), a positive bronchodilator reversibility on spirometry (p<0.05), and high-resolution computed tomography findings such as emphysema, bronchial wall thickening, bronchiectasis/bronchiolectasis, and mosaic attenuation (p<0.05). In addition, FeNO levels showed a strong positive linear correlation with serum immunoglobulin E (IgE) levels (r²=0.66, p<0.001) and AEC (r²=0.56, p<0.001). FeNO's best diagnostic cut-off level to detect T2 inflammation was 31 ppb (sensitivity: 65.9%, specificity: 86.5%; area under the receiver operating characteristic curve: 0.79). FeNO measurement, besides blood eosinophilia, is an effective, direct, airway-specific, non-invasive tool for detecting T2 airway inflammation in stable patients with COPD. Atopy (IgE sensitization) is a crucial factor in explaining higher FeNO values in COPD patients. FeNO correlates well with blood eosinophilia in COPD patients with an eosinophilic phenotype as a surrogate biomarker with good sensitivity and specificity.

  • Tuberculosis is the predominant infection in systemic sclerosis: thirty-year retrospective study of serious infections from a single centre

    by Abhishek Gollarahalli Patel, Sakir Ahmed, Jyoti Ranjan Parida, Sarit Sekhar Pattanaik, Latika Gupta, Amita Aggarwal, Able Lawrence, Durga Prasanna Misra, Alok Nath, Zia Hashim, et al.

    To look for the spectrum of infections and the factors predisposing to infection in patients with systemic sclerosis (SSc). In this retrospective study, demographic, clinical features, details of infections, immunosuppressive therapy, and outcomes of patients with SSc attending clinics at department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India from 1990 to 2022 were captured. Multivariable-adjusted logistic regression was applied to identify independent predictors of infection. Data of 880 patients, mean age 35.5 ± 12 years, and female: male ratio 7.7:1, were analyzed. One hundred and fifty-three patients had at least 1 infection with a total of 233 infectious episodes. Infections were most common in lung followed by skin and soft tissue. Tuberculosis was diagnosed in 45 patients (29.4%). Klebsiella was the commonest non-tubercular organism in lung and Escherichia coli in urinary tract infections. In comparison to matched control group, patients with infection had a greater number of admissions due to active disease, odds ratio (OR) 6.27 (CI 3.23–12.18), were receiving immunosuppressive medication OR, 5.05 (CI 2.55–10.00), and had more digital ulcers OR, 2.53 (CI 1.17–5.45). Patients who had infection had more likelihood for death OR, 13.63 (CI 4.75 -39.18). Tuberculosis is the commonest infection and lung remains the major site of infection in patients with SSc. Number of hospital admissions, digital ulcers and immunosuppressive therapy are predictors of serious infection in patients with SSc. Patients with infections had more likelihood of death.


  • Open Access

    Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: a meta-analysis of 21 studies and 5174 patients

    by Zia Hashim, Alok Nath, Ajmal Khan, Mansi Gupta, Anup Kumar, Riksoam Chatterjee, Radha Krishan Dhiman, Martin Hoenigl, Naresh Kumar Tripathy

    Objective: COVID-19-associated pulmonary aspergillosis (CAPA) remains a high mortality mycotic infection throughout the pandemic, and glucocorticoids (GCs) may be its root cause. We aimed to evaluate the effect of systemic GC treatment on the development of CAPA. Methods: We systematically searched the PubMed, Google Scholar, Scopus, and Embase databases to collect eligible studies published until December 31, 2022. The pooled outcome of CAPA development was calculated as the log odds ratio (LOR) with 95% confidence intervals (CI) using a random effect model. Results: A total of 21 studies with 5174 patients were included. Of these, 20 studies with 4675 patients consisting of 2565 treated with GC but without other immunomodulators (GC group) and 2110 treated without GC and other immunomodulators (controls) were analyzed. The pooled LOR of CAPA development was higher for the GC group than for the control group (0.54; 95% CI: 0.22, 0.86; p<0.01). In the subgroups, the pooled LOR was higher for high-dose GC (0.90; 95% CI: 0.17, 1.62: p=0.01) and dexamethasone (0.71; 95% CI: 0.35, 1.07; p<0.01)-treated patients, but there was no significant difference for low-dose GC (0.41; 95% CI: -0.07, 0.89; p=0.09)- and non-dexamethasone GC (0.21; 95% CI: -0.36, 0.79; p=0.47)-treated patients versus controls. Conclusion: GC treatment increased the risk of CAPA development, and the risk was associated with the use of high-dose GC or dexamethasone therapy.

  • Open Access

    CLINICAL CHARACTERISTICS OF PATIENTS WITH DIFFUSE ALVEOLAR HEMORRHAGE DIAGNOSED BY CYTOLOGICAL EXAMINATION OF 1000 BRONCHOALVEOLAR LAVAGE SAMPLES

    by Pallavi Prasad, Aviral Gupta, Alok Nath, Zia Hashim, Mansi Gupta, Narendra Krishnani, Ajmal Khan

    Background and aim: Diffuse alveolar hemorrhage (DAH) is a life-threatening condition due to the extravasation of blood in the alveoli, resulting in hypoxemia and even acute respiratory distress syndrome. This study aimed to describe the clinico-radio-pathological profile of patients diagnosed with DAH and classify it into immune and nonimmune DAH. Methods: This was a retrospective analytical study. Of a total of 1000 cases of bronchoalveolar lavage fluids (BALF) received for cytological examination, patients fulfilling the clinical, ra-diological, and laboratory details of cases satisfying the clinical and cytological criteria of DAH (n=47) were studied. Results: The most common cause of immune DAH was ANCA-associated vasculitis (n=13, 27.6%), and that of nonimmune DAH was infections (n=10, 21.3%). Twenty-nine patients (61.7%) had hemoptysis. The most common radiological finding was ground-glass opacities (n=33, 70.2%). In univariate analysis, female sex, mean hemoglobin at admission, total leucocyte count (TLC), platelet count, and erythrocyte sedimentation rate (ESR) were significantly associated with immune-DAH. However, in multivariate analysis, female sex, higher TLC, high platelets, and high ESR were significantly associated with immune DAH. Patients were treated with corti-costeroids (n=25, 46.3%), intravenous cyclophosphamide (n=12, 22.2%), plasma exchange (n=7, 13.0%), intrave-nous immunoglobulin (n=5, 9.3%) and rituximab (n=5, 9.3%). The overall mortality was 8.5% (n=4). Conclusions: DAH is a life-threatening syndrome that may be classified into immune and nonimmune DAH. Immune-DAH requires aggressive management, whereas nonimmune DAH cases respond best to conservative management.


  • Open Access

    Initial Experience of Endobronchial Silicon Stents from a Tertiary Care Centre in North India

    by R. Agarwal, N. Singh, A.N. Aggarwal, D. Gupta, A. Khan, H. Bhagat, B. Kumar, L.N. Yaddanapudi, S. Sethi, N. Khandelwal

    Central airway obstruction (CAO) is defined as obstruction of trachea and principal bronchi. Therapeutic rigid bronchoscopy with tracheobronchial stenting using silicon stents is a well established procedure in the management of such conditions. However, there is limited experience with this technique in India. Between January 2010 and April 2010, Dumon stents were placed in four patients with CAO. Three patients had symptomatic tracheal stenosis while one patient had malignant obstruction at the carina. Rigid bronchoscopy under general anaesthesia was performed to relieve the CAO followed by placement of silicon stents. Pre- and post-stent placement symptom assessment was performed with a symptom-based visual analogue scale. Four patients underwent silicon stent placement in the tracheobronchial tree. Three patients had benign post-intubation tracheal stenosis and one had malignant tracheal obstruction at carina due to endobronchial growth. Significant improvement was achieved in all patients. There were no significant complications. Rigid bronchoscopy with silicon stent placement is an effective and suitable method of relieving the distressing symptoms due to benign or malignant airway obstruction.


  • Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma

    by Ravi Mishra, Rachna Chaturvedi, Zia Hashim, Alok Nath, Ajmal Khan, Mansi Gupta, Harshit Singh, Vikas Agarwal

    Introduction: Resistance to corticosteroid is an essential mechanism in uncontrolled asthma as the corticosteroid is the mainstay of therapy. There are recent reports that epigenetic factors play a crucial role in the regulation of steroid action. Overexpression of P glycoprotein (P-gp) and reduced expression of Histone Deacetylase 2 (HDAC2) have been linked to regulating the steroid action in other diseases like Nephrotic Syndrome (NS). However, their role in uncontrolled asthma is still not clear and warrants further investigation. We evaluated the expression and activity of P-gp and HDAC2 in patients with Controlled Asthma (CA) and Uncontrolled Asthma (UA). Methods: A total of 60 CA (mean age 51.72±17.02 years, male=38), and 38 of UA (mean age=53.55±11.90 years, male=17) were recruited. The level of control was defined according to (Global Initiative for Asthma) GINA 2016 criteria. The mRNA expression of HDAC2 and P-gp was studied by quantitative real-time Polymerase Chain Reaction (PCR), the functional activity of P-gp was evaluated by a commercially available kit via flow cytometry, and HDAC2 enzymatic activity was measured by commercially available kit by Enzyme-Linked Immunosorbent Assay (ELISA). Results: P-gp expression and the functionality were significantly higher in the UA group of patients as compared to the CA group of patients (p<0.005), moreover HDAC2 expression was significantly reduced in UA patients as compared to CA patients, (p<0.005). The enzymatic activity of HDAC2 was also significantly reduced in UA patients as compared to CA patients (p<0.005). Conclusion: P-gp overexpression and HDAC2 under expression play an essential role in uncontrolled asthma by impairing the response to corticosteroid.